BACKGROUND: Neuroblastomas (NBs) are the most common solid cancer of childhood and infancy; however, in poorly differentiated forms, they present diagnostic challenges. GATA3 has been implicated functionally in NB differentiation, and limited data support its use as an immunohistochemical biomarker for NBs in resection specimens. METHODS:
INTRODUCTION
Neuroblastomas (NBs) are the most common extracranial solid cancer of childhood and infancy. The classic microscopic morphology is a "small, round, blue cell tumor" consisting of small-to-medium tumor cells dominated by a nucleus exhibiting salt and pepper chromatin. There is often an indiscernible amount of cytoplasm with indistinct borders. Varying degrees of differentiation, correlated with background quantities of neuropil and evidence of nuclear and cytologic differentiation toward a gangliocytic morphology, may be helpfully present in some cases. However, poorly differentiated NBs frequently show only limited cytomorphologic clues to the diagnosis, whereas in undifferentiated cases, immunohistochemistry to exclude other undifferentiated small round cell neoplasms, such as Ewing sarcoma, rhabdomyosarcoma, and nephroblastoma, is frequently necessary. 1 Frequently, diagnostic material is also limited because contemporary pediatric tumor protocols, including protocols for NBs, require triaging of tumor samples for multiple prognostic molecular markers, including the MYCN status, 11q status, ALK amplification or mutations, and ploidy. 2 The diagnosis of NB must be efficient and preserve as much tissue as possible; this necessitates a highyield immunohistochemical armamentarium. GATA3 is a transcription factor associated with mammary epithelial, urothelial, epidermal, and even normal 3 and neoplastic T-cell populations. [4] [5] [6] Despite its multispecificity, GATA3 has demonstrated remarkable utility as an immunohistochemical marker in identifying neoplasms in surgical pathology, most especially those of mammary and urothelial origins. 7, 8 This marker exhibits strong, consistent nuclear staining in appropriate target tissues. With respect to NBs, functional studies suggest that GATA3 may be a key (negative) regulator of differentiation in NBs by inducing the proliferation and tumorigenicity of NB cells. 9, 10 Recently, one report examined the expression of GATA3 across the full spectrum of neoplasms of the autonomic nervous system, and through a whole section-based study, it found GATA3 to be a very promising marker for this group, including paragangliomas, pheochromocytomas, and neuroblastic tumors, without significant expression in many simulants of these tumors, especially neuroendocrine tumors.
11
Given that aspiration is well established as a diagnostic modality for pediatric tumors 12 and given the increased use of image-guided aspiration and core biopsy for NBs at our institution, we retrospectively evaluated the utility of GATA3 in cytologic samples, including cell block preparations and small biopsies. In addition, given the limited tissue samples often evaluated, we tested GATA3 as a marker for NBs in air-dried touch imprints, an application of immunocytochemistry that has not been previously reported for this marker.
MATERIALS AND METHODS
This study was a retrospective diagnostic biomarker study, approved by the institutional review board at our institution, of consecutive archival NB samples, including small (subcentimeter) surgical pathology samples, cytology cell blocks, and touch preparation slides. GATA3 immunostaining (mouse monoclonal antibody [clone L50-823] from Biocare, Pacheco, California) was performed with a Dako Omnis instrument according to our routine, Clinical Laboratory Improvement Amendments-compliant, automated staining protocol (predilution and 30-minute incubation after 30 minutes of high-pH antigen retrieval). We tested GATA3 immunohistochemistry on a total of 30 samples taken from 22 NB specimens, including recut sections of archival cytopathology cell blocks (n 5 6), tissue microarrays of 2-mm NB tissue cores (n 5 11; taken from separate areas of 3 separate specimens), and scant surgical biopsies (n 5 5).
In addition, we tested GATA3 immunocytochemistry on unstained, air-dried touch imprints (smears of biopsy or excision specimens) of NBs (n 5 8) with unstained, archived air-dried slides. These slides were routinely prepared during our department's pediatric tumor gross protocol and were stored (from 2 months to > 3 years for those studied herein) in darkness with the rest of the routine hematoxylin-eosin slides in our slide archive room at 21 8C with an average daily humidity of 60%. The unstained, unbaked, air-dried touch imprints were rehydrated and fixed in formalin for 1 hour, as reported previously, 13, 14 before the use of our standard immunohistochemistry staining protocol. Unstained touch imprints of other tissues (thyroid and liver) were used as negative controls for the assay. In addition, a tissue microarray of triplicate 2-mm cores of small round cell sarcomas (n 5 32; Ewing sarcoma, alveolar rhabdomyosarcoma, and high-grade myxoid liposarcoma) in the morphologic differential with NB, as reported previously, 15 was stained. The staining pattern was evaluated semiquantitatively by intensity as 0 (no staining), 1 (weak staining), 2 (moderate staining), or 3 (strong staining) and by proportion as 0 (no staining), 1 (focal staining, <10%), 2 (multifocal staining, 10%-75%), or 3 (diffuse staining, > 75%).
RESULTS
Overall, 30 samples from 22 NB cases, including 14 from male patients and 8 from female patients, were retrospectively identified and tested for GATA3. These included 7 (32%) with a favorable histology, 10 (45%) with an unfavorable histology, 4 (18%) with metastases or recurrences, and 1 (5%) with composite-type NB according to the International Neuroblastoma Pathology Prognostic Classification. Regardless of the degree of differentiation, all NB cases tested, including all samples of undifferentiated NB (3 or 14%), poorly differentiated NB (10 or 45%), differentiating NB (4 or 18%), recurrent/metastatic NB (4 or 18%), and composite NB (1 or 5%), showed diffuse nuclear positivity for GATA3 (see Table 1 ). Each sample revealed either strong-(n 5 26) or moderate-intensity nuclear staining (n 5 4) in the NB, even in the presence or lack of stromata and necrosis. In all 30 samples, diffuse staining (>75% of NB cell nuclei) was observed. Of the 22 paraffin-embedded
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The TMA uses replicate cores sampling multiple areas of the tumor to evaluate the tumor for heterogeneity.
samples, 21 demonstrated strong nuclear staining (Fig. 1) . Of the 8 air-dried touch imprints, 5 demonstrated strong staining, whereas 3 demonstrated moderate staining (Fig.  2) . No small round cell sarcomas in the differential with NB stained positively (0 of 9 rhabdomyosarcomas, 0 of 9 Ewing sarcomas, and 0 of 8 high-grade myxoid liposarcomas).
DISCUSSION
In most cases of NB and ganglioneuroblastoma, a diagnosis can be established by a combination of histopathology, laboratory measurements of catecholamines, and clinicopathologic correlation with the anatomic location. However, our experience has been that, in many cases, the classification of pediatric small round cell neoplasms remains a challenge, particularly with limited samples available for diagnosis or for the documentation of recurrence. 16 In particular, undifferentiated NBs, which by definition should show essentially no recognizable ganglionic differentiation, essentially require ancillary immunohistochemical techniques to confirm the diagnostic impression. Thus, several immunostains, particularly 
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synaptophysin, chromogranin, and clone NB84, have been proposed for use in the differential diagnosis for this lesion. Although these immunostains have significant utility for the diagnosis of undifferentiated and poorly differentiated NBs, [17] [18] [19] [20] [21] substantial reported pitfalls remain, particularly with respect to synaptophysin, with which a subset 22 to even a majority of Ewing sarcomas 23 stain positively. Similarly, a minority of alveolar rhabdomyosarcomas (approximately 20%-30%) stain positively for chromogranin and synaptophysin. 24 For these reasons, authors have generally recommended the use of panels of immunostains for poorly differentiated and undifferentiated NBs. In tumors with little or no evidence of neuronal differentiation, the exclusion of the expression of markers more specific to other entities in the morphologic differential, especially Ewing sarcoma, may be of use. 25 To us, for such poorly differentiated cases, the recent observation of a mechanistic role for GATA3 as a key mediator of the undifferentiated and proliferative phenotype is particularly salient. The differentiation of NB cells has been shown to be actually associated with decreased expression of GATA3, 10 which is thought to help to mediate a pluripotent and proliferative state in these cells. 26 This is the pattern of expression observed in the only published study investigating GATA3 as an immunohistochemical marker for tumors of the autonomic nervous system, in which Nonaka et al 11 reported diffuse expression in all 13 NBs and ganglioneuroblastomas (all whole archival tissue sections) as well as 8 of 8 ganglioneuromas, 31 of 35 paragangliomas, and 20 of 21 pheochromocytomas. We note that multiple recent studies have noted rather pervasive GATA3 expression in paragangliomas as well. 7, 27, 28 Our findings confirm this impression of ubiquitous expression of GATA3 in NBs in a larger cohort of challenging specimen types and the pervasive, diffuse expression of GATA3 across the spectrum of NB differentiation. We observed diffuse, moderate or strong expression in all cases studied, and this was readily interpreted in cell block preparations, needle cores, small biopsies, and tissue microarray cores. Moreover, and perhaps most usefully for cases in which diagnostic material is at a premium, we report the implementation of this stain in immunocytochemistry with air-dried touch imprints, which can spare tissue for other studies and are already routinely prepared by many institutional pediatric tumor gross processing protocols.
It is helpful too for the small round cell differential that prior reports have reported no positivity for GATA3 in several important lesions in the differential. The GATA3 stain was diffusely positive in air-dried direct smears (touch imprints) of a neuroblastoma (original magnification 3 400). (B) In another case, the GATA3 stain had moderate intensity and was diffusely positive; scattered internal negative-control mononuclear cells were visible and admixed with the neuroblastoma cells (original magnification 3 400; zoomed). Note the retained positive nuclear staining in both examples despite the limited preservation of cytomorphologic detail in these preparations.
7 epithelioid sarcomas, 7 rhabdomyosarcomas, and 3 myxoid liposarcomas. Our tissue microarray study provides further confirmation in this respect: we observed no positivity in Ewing sarcomas (n 5 9), rhabdomyosarcomas (n 5 9), or high-grade round cell liposarcomas (n 5 8).
We acknowledge the limitations of the current study, which, though larger than a prior cohort, includes relatively few cases of differentiating NBs and no ganglioneuroblastomas. Also, we have not demonstrated GATA3 staining on alcohol-fixed slides or with any liquid-based preparations (because of the lack of any such examples to test at our institution), and thus we cannot recommend GATA3 as a first-line marker in these settings. (Indeed, we recommend careful onsite validation of the performance characteristics of any immunohistochemical test in the laboratory setting and for the case types intended for use.) Lastly, we emphasize that our usage of a tissue microarray format to test 11 samples was meant to simulate the limitations of tiny biopsy samples. Certainly, such findings cannot be deemed to represent 11 independent tests but rather can be used to assess any issues with patchy or variable staining such as might arise in the setting of a core biopsy sample or other small sample from a larger tumor.
In summary, on the basis of these findings, we currently regard GATA3 as a first-line immunohistochemical stain for the support of the diagnosis of NBs, including poorly differentiated NBs, even in limited aspiration samples in the setting of recurrence. Indeed, we interpret these findings as supportive of the practice of making additional air-dried touch imprints at the time of rapid onsite evaluations when NB is in the differential. In particular, the distinct and strong nuclear staining of GATA3 in cytologic NB specimens can help to overcome the limitations of poor structural preservation, which often accompanies small biopsy specimens and air-dried imprints for this tumor type. GATA3 has the distinct and paradoxical advantage of strong, diffuse expression, even in the least differentiated cases, which often show little morphologic evidence of gangliocytic differentiation to help to establish the diagnosis. Although initial reports 3,30 describing GATA3 suggested a high degree of specificity of expression for mammary and urothelial lesions, with much interest, a (somewhat disappointingly) expanded spectrum of positivity in tumors of other sites has lately been documented. 7, 31 Our findings further document the multispecific nature of this marker 7 ; however, for an NB diagnosis, we find that sometimes the exceptions may be just as useful as the rules.
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